Janux Therapeutics Inc (JANX)
Janux Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing immunotherapy candidates for cancer and autoimmune disease. Its research programs are built around its TRACTr, TRACIr, and ARM platforms, which are designed to support tumor-activated immune responses. The company’s pipeline includes JANX007, a PSMA-targeted candidate being studied in Phase 1 trials for metastatic castration-resistant prostate cancer and other tumors, and JANX008, which is in Phase 1 testing across several solid tumor types. Janux is also advancing JANX011, a CD19-targeted candidate under Phase 1 evaluation for autoimmune diseases. In addition, the company has collaboration agreements with Merck Sharp & Dohme Corp. and Bristol Myers Squibb. Janux Therapeutics was incorporated in 2017 and is based in San Diego, California.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-JANX
|
$20.88
|
29.6% Upside
|
Undervalued
|
$37.19
|
130.8% Upside
|
Bargain
|
Good
|
—
|
—
|
—
|
0.0%
|
August 11, 2026
|
-8.6x
|
1.0x
|
71.5x
|
978.8 M
|
47.643 M
|
2.2%
|
64.2%
|
6.9
|
—
|
68.6%
|
